Long-term efficacy of erenumab in patients with episodic migranie who have failed prior preventive migraine therapies
Year: 2019
Type: conference-paper
Abstract: Objective: To assess the sustained efficacy of erenumab through 52 weeks of treatment in patients with episodic migraine who had failed prior preventive therapies (EMTF). Background: Erenumab has demonstrated efficacy and safety in migraine prevention studies. Design/Methods: Patients were randomized (1:1:1; n=955) to placebo or erenumab 70mg or 140mg monthly during the 24-week, double-blind treatment phase (DBTP) of the STRIVE study (NCT02456740). At week 24, 845 patients were re-randomized (1:1) to erenumab 70mg or 140mg for the subsequent 28-week, dose-blinded active treatment phase (ATP). The EMTF subgroup was defined as patients who failed ≥ one prior preventive therapy due to lack of efficacy/tolerability. Change from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication treatment days (MSMD) were assessed at week 52, as well as the proportion of patients achieving ≥50%/≥75%/100% MMD reduction in the last month of ATP. Patients were analyzed by dose received during the ATP (70mg or 140mg) for efficacy and safety reporting, irrespective of DBTP treatment. Results: Of the 845 patients who completed the DBTP and were re-randomized into the ATP, 343 (41%) patients had failed ≥ one prior preventive therapy. In EMTF, baseline MMD was 8.7(0.1); mean (SE) change from baseline to week 52 was −3.4(0.4) and −4.2(0.3) for the 70mg and 140mg erenumab dose groups, respectively. Baseline MSMD was 4.9(0.2); mean (SE) change from baseline to week 52 in MSMD was −1.9(0.3) and −2.5(0.2) for 70mg and 140mg erenumab, respectively. In total, 52.3% of EMTF patients on erenumab 70mg and 55.0% of EMTF patients on erenumab 140mg achieved ≥50% reduction from baseline in MMD at Week 52; 29% and 33% achieved ≥75% reduction, and 12% and 16% achieved 100% reduction. Conclusions: Erenumab provided sustained efficacy through week 52 in patients with episodic migraine who had failed prior preventive migraine therapy. Disclosure: Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals. Dr. Reuter’s institution has received research support for participation in clinical trials. Dr. Schwedt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, ATI, Aural Analytics, Avanir, Dr. Reddy’s Laboratories, Eli Lilly, Ipsen Bioscience, Nocira, Novartis, Promius Pharma, Second Opinion, and Teva. Dr. Schwedt has received personal compensation in an editorial capacity for Associate Editor for Headache, Pain Medicine, and Cephalalgia journals. Dr. Kudrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Eli Lilly, Amgen, Promius and AOBiome. Dr. Kudrow has received research support from Amgen, Alder, Ely Lilly, Teva, Roche-Genentech, Allergan, Biohaven, UCB, and Viromed. Dr. Paemeleire has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen/Novartis, Lilly, Teva, Allergan, and Autonomic Technologies Inc. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen. Dr. Zhang has received compensation for serving on the Board of Directors of Amgen. Dr. Zhang holds stock and/or stock options in Amgen Inc. Dr. Klatt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Klatt has received compensation for serving on the Board of Directors of Novartis. Dr. Picard has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen. Dr. Picard holds stock and/or stock options in Amgen which sponsored research in which Dr. Picard was involved as an investigator. Dr. Chou has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen Inc. Dr. Chou holds stock and/or stock options in Amgen Inc. Dr. Mikol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen. Dr. Mikol has received compensation for serving on the Board of Directors of Amgen. Dr. Mikol holds stock and/or stock options in Amgen Inc. which sponsored research in which Dr. Mikol was involved as an investigator. Dr. Mikol holds stock and/or stock options in Amgen Inc.
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3093820723